๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› B-cell Lymphoma
Clinical trial register · China

B-cell Lymphoma Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 9 Guangzhou 6 Harbin 3 Shanghai 3 Wuhan 3
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing9 Guangzhou6 Harbin3 Shanghai3 Wuhan3
All 25 locations
Target enrolment
to

B-cell Lymphoma trials in China

20 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
In Vivo CD19/CD20 CAR T-Cell Therapy for Relapsed/Refractory B-Cell Lymphoma
NCT07775508B-cell Lymphoma
Chinese PLA General Hospital
Phase 1
18
Beijing
2026-06-01
Not yet open
Phase I Study of FXS0683 in the Treatment of Blood Tumors
NCT07616089B-Cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Lymphoblastic Leukemia
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Phase 1
228
Tianjin
2026-06-01
Recruiting
Anti CD19 Gene Therapy for B-cell Lymphoma
NCT07211048B-cell Lymphoma
Anhui Provincial Hospital
Not applicable
18
Hefei
2026-03-20
Recruiting
CD30 CAR-T in the Treatment of CD30 Positive Lymphoma
NCT07048353Lymphoma, B Cell Lymphoma, CD30+ Peripheral T-cell Lymphoma
Shandong Qilu Cell Therapy Engineering Technology Co., Ltd
Phase EARLY_PHASE1
15
Wuhan
2026-03-01
Recruiting
Safety and Efficacy Study of BAFF-R CAR-T Cells in Adult Subjects With CD19-Negative Relapsed or Refractory B-Cell Lymphoma
NCT07369492B-cell Lymphoma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Phase 1
30
Suzhou
2026-01-01
Recruiting
Zanubrutinib Combined With Rituximab in the Treatment of Secondary HLH in B-cell Lymphoma
NCT07270835Hemophagocytic Lymphohistiocytosis, B Cell Lymphoma
The First Affiliated Hospital of Soochow University
Phase 4
40
Suzhou
2025-11-01
Active, closed
Long-Term Safety of Pirtobrutinib in Participants With Previously Treated Types of Blood Cancers
NCT07162181Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, B-cell Lymphoma
Eli Lilly and Company
Phase 2
13
Beijing, Guangzhou, Harbin, Shanghai, Tianjin, Wuhan
2025-08-07
Recruiting
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma
NCT07009002B Cell Lymphoma
Chinese PLA General Hospital
Phase 1/2
30
Beijing
2025-06-20
Recruiting
A Clinical Study of Allogeneic CD19/BCMA CAR-T Cells for the Treatment of R/R B-cell Malignant Tumors
NCT06976437B Cell Lymphoma, Multiple Myeloma
YANRU WANG
Phase EARLY_PHASE1
21
Zhenjiang
2025-05-06
Recruiting
Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma
NCT06987916B Cell Lymphoma
Shanghai Tongji Hospital, Tongji University School of Medicine
Phase 1/2
50
Shanghai
2025-04-22
Recruiting
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996Mantle Cell Lymphoma, B Cell Lymphoma
BeOne Medicines
Phase 3
300
Beijing, Chongqing, Guangzhou, Harbin, Zhengzhou, Wuhan, Nanjing, Xuzhou
2025-03-05
Recruiting
Clinical Study of U01๏ผˆssCART-19๏ผ‰ in Patients With B-Cell Lymphoma
NCT07093073B Cell Lymphoma
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase 1
30
Shanghai
2025-01-23
Recruiting
Safety and Efficacy of Fourth-Generation CAR-T in the Treatment of Hematologic Malignancies
NCT06758713Multiple Myeloma, B-cell Lymphoma, Hematological Malignancy
DrugCar-T
The Third Affiliated Hospital of Southern Medical University
Phase 1
60
Guangzhou
2025-01-15
Recruiting
A Study of XS-04 in Patients with Relapsed or Refractory Hematologic Malignancies
NCT06820268B-cell Lymphoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome
NovaOnco Therapeutics Co., Ltd.
Phase 1
168
Beijing, Guangdong, Hebei, Hubei
2025-01-14
Recruiting
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
NCT06634589B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
BeOne Medicines
Phase 1/2
80
Fuzhou, Guangzhou, Suzhou, Hangzhou, Wenzhou
2024-11-27
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of TQB3702 Tablets Combined With Immunochemotherapy for the Treatment of B-cell Lymphoma
NCT06566586B-cell Lymphoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
80
Beijing, Lanzhou, Guangzhou, Guigang, Nanning, Harbin, Anyang, Puyang
2024-11-06
Recruiting
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
NCT07584889B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase 1/2
10
Shenzhen
2024-04-20
Recruiting
Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
NCT06180174B Cell Lymphoma, Non Hodgkin Lymphoma
Chongqing Precision Biotech Co., Ltd
Phase 1
24
Beijing
2023-12-31
Recruiting
CD19/CD22 Bispecific CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma or Acute Lymphoblastic Leukemia
NCT06081478B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma, Diffuse Large B Cell Lymphoma
Beijing Tongren Hospital
Phase 2
100
Beijing
2022-01-18
Recruiting
A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma
NCT04993690B-cell Lymphoma
Guangzhou Lupeng Pharmaceutical Company LTD.
Phase 1
200
Beijing, Guangzhou
2021-07-06
Rows per page Showing 1–20 of 20
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/condition/b-cell-lymphoma

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 20 of those studies listing the condition B-cell Lymphoma.

How many B-cell Lymphoma trials are recruiting in China?

18 of the 20 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (B-cell Lymphoma), 20 studies
PhaseStudiesRecruitingShare
Phase 18740%
Phase 1/24420%
Phase 23215%
Phase EARLY_PHASE12210%
Not applicable115%
Phase 3115%
Phase 4115%

Most active sponsors

Lead sponsors with the most studies (B-cell Lymphoma)
Lead sponsorStudiesRecruiting
BeOne Medicines22
Chinese PLA General Hospital22
Anhui Provincial Hospital11
Beijing Tongren Hospital11
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.11
Chongqing Precision Biotech Co., Ltd11
Eli Lilly and Company10
Guangzhou Lupeng Pharmaceutical Company LTD.11
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.11
NovaOnco Therapeutics Co., Ltd.11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.